Patent application number | Description | Published |
20100068259 | NATURAL PRODUCT INHIBITORS OF 3DG - Compositions are disclosed which have as a component thereof an inhibitor of the enzymatic production of 3-deoxyglucosone (3DG) from fructoselysine and/or an inactivator of 3DG, and which are useful for the treatment or prophylaxis of a condition or disease state that is alleviated by inhibiting such 3DG production. Methods of using such compositions, e.g., for improving the appearance, texture and/or elasticity of aging skin, are also disclosed. | 03-18-2010 |
20100297046 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors - The invention relates to compounds and methods for inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin, by way of fructosamine-3-kinase inhibition, thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress. | 11-25-2010 |
20120231071 | NATURAL PRODUCT INHIBITORS OF 3DG - Compositions are disclosed which have as a component thereof an inhibitor of the enzymatic production of 3-deoxyglucosone (3DG) from fructoselysine and/or an inactivator of 3DG, and which are useful for the treatment or prophylaxis of a condition or disease state that is alleviated by inhibiting such 3DG production. Methods of using such compositions, e.g., for improving the appearance, texture and/or elasticity of aging skin, are also disclosed. | 09-13-2012 |
20130266638 | NATURAL PRODUCT INHIBITORS OF 3DG - Compositions are disclosed which have as a component thereof an inhibitor of the enzymatic production of 3-deoxyglucosone (3DG) from fructoselysine and/or an inactivator of 3DG, and which are useful for the treatment or prophylaxis of a condition or disease state that is alleviated by inhibiting such 3DG production. Methods of using such compositions, e.g., for improving the appearance, texture and/or elasticity of aging skin, are also disclosed. | 10-10-2013 |
Patent application number | Description | Published |
20080275097 | Non-nucleoside reverse transcriptase inhibitors - Compounds of Formula I: | 11-06-2008 |
20100087419 | HIV INTEGRASE INHIBITORS - Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: | 04-08-2010 |
20100240721 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF - The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods for the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. | 09-23-2010 |
20110263663 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF - The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods for the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. | 10-27-2011 |
20120022045 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS - Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: the asterisk * in Q denotes the point of attachment to the rest of the compound; and n, L1, L2, X | 01-26-2012 |
20120220571 | HIV INTEGRASE INHIBITORS - Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I), wherein X is O or N(R3); and R1, R2, R3 and Y are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. | 08-30-2012 |
20130338141 | HIV INTEGRASE INHIBITORS - Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: | 12-19-2013 |
Patent application number | Description | Published |
20140343956 | Linking the Role of Integrated Delivery Networks to Prescriber Behavior - The disclosure generally describes computer-implemented methods, software, and systems for identifying the role of Integrated Delivery Networks (IDNs) in determining prescriber behavior. An IDN is a network of facilities and providers that work together to offer a continuum of care to a specific geographic area or market, and is a type of managed care organization. The disclosure relates to implementations that facilitate the accessing of information from actors within a health care system and processing the information by an analytical infrastructure. | 11-20-2014 |
20150058028 | Identifying Performance Levels of a Product Within Integrated Delivery Networks - The disclosure generally describes computer-implemented methods, software, and systems for identifying the role of Integrated Delivery Networks (IDNs) in determining prescriber behavior, using an analytical and reporting infrastructure. The disclosure also describes determining a model role for the prescribing behavior of the prescribers affiliated with an IDN to establish a performance level of a drug. | 02-26-2015 |
20150058029 | Identifying Performance Levels of a Product Within Integrated Delivery Networks - The disclosure generally describes computer-implemented methods, software, and systems for modeling the possible outcomes of a negative event in the market place. A negative event may be any event that has a negative impact on the marketshare value for a product in a territory. The disclosure also describes, presenting marketing investments that will reduce impact on the marketshare based on the occurrence of a negative event, by an analytical infrastructure. | 02-26-2015 |
20150127357 | Interactive Behavior of Corporate Parents and Managed Care Organizations - The disclosure generally describes computer-implemented methods, software, and systems for measuring and quantifying the interactive effect of corporate parents and managed care organizations on pharmaceutical product performance. The disclosure relates to implementations that facilitate the accessing of information from actors within a health care system and processing the information by an analytical infrastructure. | 05-07-2015 |
Patent application number | Description | Published |
20090043804 | Storing table data - In some embodiments, the grid definition and data source definition portions of a table definition are segregated. Grid definition values included in the grid definition portion include one or more grid geometry values and/or grid line style values. Cell content values included in the data source definition portion include one or more data values and/or cell-specific style values. | 02-12-2009 |
20090044093 | Cutting and copying discontiguous selections of cells - Cutting and copying discontiguous selections of cells is disclosed. In some embodiments, in response to receiving an indication of a selection of a set of cells that does not include only a continuous grid of selected cells and receiving an indication of a selection of a paste destination in which the set of cells is desired to be pasted, the set of cells is pasted in the paste destination in a manner that preserves a respective relative position of each cell in the set. In some embodiments, if a paste destination is not large enough to accommodate a paste operation, the paste destination is automatically expanding so that it is large enough to accommodate the paste operation. | 02-12-2009 |
20110202823 | PASTING A SET OF CELLS - Pasting a set of cells is disclosed. In some embodiments, a selection of an option to paste a set of cells in a paste destination is received; and in response to determining that the paste destination is not large enough to accommodate a paste operation associated with the selected option, the paste destination is automatically expanded so that the paste destination is large enough to accommodate the paste operation. | 08-18-2011 |
Patent application number | Description | Published |
20100285469 | METHOD OF TUMOR SCREENING - A method for tumor screening using urine of a mammal, the method includes obtaining a total urine nucleic acid (e.g., DNA) from a urine sample of a mammal, extracting a high molecular weight urine nucleic acid (above 1000 bp) by contacting the total urine nucleic acid with an adsorbent in the presence of a buffer which promotes binding of the high molecular weight urine nucleic acid to the adsorbent, replacing the buffer which promotes binding of the high molecular weight urine nucleic acid with a buffer which promotes binding of the low molecular weight urine nucleic acid to the adsorbent, extracting the low molecular weight urine nucleic acid by contacting with the adsorbent, eluting the low molecular weight urine nucleic acid, and assaying the low molecular weight urine nucleic acid for a presence or absence of a gene sequence specific to a certain type of tumor. | 11-11-2010 |
20110256538 | EPIGENOMIC DNA MODIFICATIONS FOR TISSUE TYPING, EARLY CANCER DETECTION, AND DISEASE MANAGEMENT - Provided herein is a suitable method for detecting the presence or absence of a cancer in an individual, by determining the level of methylation of the sense strand of a selected regulatory region of a tumor suppressor gene. Also provided herein is a method of detecting the presence or absence a cancer in an individual by determining if there is an apparent 100% methylation by assay of the CpG sites in the anti-sense strand of a selected regulatory region of a tumor suppressor gene. Also provided herein is a method of tissue typing by determining the level of methylation of the anti-sense strand of a selected regulatory region of a tumor suppressor gene indicating an enhanced likelihood that a tissue is liver. | 10-20-2011 |
20130130244 | P53 ASSAY FOR A URINE TEST FOR HCC SCREENING - A rapid and sensitive assay to detect p53 mutations in urine has been developed for use in screening cancer patients. The method uses a locked nucleic acid (LNA) clamp mediated one-step PCR-based assay with a sensitivity of up to a single copy and can be used not only in urine, but also other biological samples. The assay is particularly useful for hepatocellular carcinoma, colon cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, bladder cancer, lymphoma, and stomach cancer. | 05-23-2013 |
20140335529 | METHOD OF TUMOR SCREENING - A method for tumor screening using urine of a mammal, the method includes obtaining a total urine nucleic acid (e.g., DNA) from a urine sample of a mammal, extracting a high molecular weight urine nucleic acid (above 1000 bp) by contacting the total urine nucleic acid with an adsorbent in the presence of a buffer which promotes binding of the high molecular weight urine nucleic acid to the adsorbent, replacing the buffer which promotes binding of the high molecular weight urine nucleic acid with a buffer which promotes binding of the low molecular weight urine nucleic acid to the adsorbent, extracting the low molecular weight urine nucleic acid by contacting with the adsorbent, eluting the low molecular weight urine nucleic acid, and assaying the low molecular weight urine nucleic acid for a presence or absence of a gene sequence specific to a certain type of tumor. | 11-13-2014 |